drugset / Trial / NCT03120247

Pharmacokinetics and Pharmacodynamics of Oral Transmucosal Dexmedetomidine.

NCT03120247

Phase 2/3 Completed 36 enrolled Assiut University
RandomizedParallel-groupDouble-blindTreatment

Summary

Oral trans-mucosal administration is relatively easy and convenient, it also reduces first pass metabolism and has been used successfully for fentanyl, ketamine, and midazolam premedication.

Timeline

Start
2017-04-05
Primary completion
2019-06-01
Completion
2019-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dexmedetomidine Other / unclassified 0.5 ug/kg Oral
Comparator Dexmedetomidine Other / unclassified 0.75 ug/kg Oral
Comparator Dexmedetomidine Other / unclassified 1 ug/kg Oral

Indications

No indication recorded.